ORIGINAL_ARTICLE
Monitoring Frameworks for Universal Health Coverage: What About High-Income Countries?
Implementing universal health coverage (UHC) is widely perceived to be central to achieving the Sustainable Development Goals (SDGs), and is a work program priority of the World Health Organization (WHO). Much has already been written about how low- and middle-income countries (LMICs) can monitor progress towards UHC, with various UHC monitoring frameworks available in the literature. However, we suggest that these frameworks are largely irrelevant in high-income contexts and that the international community still needs to develop UHC monitoring framework meaningful for high-income countries (HICs). As a first step, this short communication presents preliminary findings from a literature review and document analysis on how various countries monitor their own progress towards achieving UHC. It furthermore offers considerations to guide meaningful UHC monitoring and reflects on pertinent challenges and tensions to inform future research on UHC implementation in HIC settings.
https://www.ijhpm.com/article_3612_988cd058cded3fc081565a02b039f73d.pdf
2019-07-01
387
393
10.15171/ijhpm.2019.21
Universal Health Coverage
High-Income Countries
Sustainable Development Goals
Monitoring
Nicole
Bergen
nicolejbergen@gmail.com
1
Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada
LEAD_AUTHOR
Arne
Ruckert
aruckert@uottawa.ca
2
Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada
AUTHOR
Ronald
Labonté
rlabonte@uottawa.ca
3
Canada Research Chair, Globalization and Health Equity, Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada
AUTHOR
Tangcharoensathien V, Mills A, Palu T. Accelerating health equity: the key role of universal health coverage in the Sustainable Development Goals. BMC Med. 2015;13:101. doi:10.1186/s12916-015-0342-3
1
Organization for Economic Cooperation and Development. Universal Health Coverage and Health Outcomes. Paris: OECD; 2016. https://www.oecd.org/els/health-systems/Universal-Health-Coverage-and-Health-Outcomes-OECD-G7-Health-Ministerial-2016.pdf. Accessed June 25, 2018.
2
Universal health coverage (UHC). World Health Organization website. http://www.who.int/news-room/fact-sheets/detail/universal-health-coverage-(uhc). Published 2018. Accessed May 29, 2018.
3
McKee M, Balabanova D, Basu S, Ricciardi W, Stuckler D. Universal health coverage: a quest for all countries but under threat in some. Value Health. 2013;16(1 Suppl):S39-45. doi:10.1016/j.jval.2012.10.001
4
Whiteside H. Canada’s health care “crisis”: Accumulation by dispossession and the neoliberal fix. Stud Polit Econ. 2009;84(1):79-100. doi:10.1080/19187033.2009.11675047
5
Borgonovi E, Compagni A. Sustaining universal health coverage: the interaction of social, political, and economic sustainability. Value Health. 2013;16(1 Suppl):S34-38. doi:10.1016/j.jval.2012.10.006
6
Fullman N, Lozano R. Towards a meaningful measure of universal health coverage for the next billion. Lancet Glob Health. 2018;6(2):e122-e123. doi:10.1016/s2214-109x(17)30487-4
7
Hogan DR, Stevens GA, Hosseinpoor AR, Boerma T. Monitoring universal health coverage within the Sustainable Development Goals: development and baseline data for an index of essential health services. Lancet Glob Health. 2018;6(2):e152-e168. doi:10.1016/s2214-109x(17)30472-2
8
Lai T, Habicht T, Jesse M. Monitoring and evaluating progress towards Universal Health Coverage in Estonia. PLoS Med. 2014;11(9):e1001677. doi:10.1371/journal.pmed.1001677
9
Aguilera X, Castillo-Laborde C, Ferrari MN, Delgado I, Ibanez C. Monitoring and evaluating progress towards universal health coverage in Chile. PLoS Med. 2014;11(9):e1001676. doi:10.1371/journal.pmed.1001676
10
Tan KB, Tan WS, Bilger M, Ho CW. Monitoring and evaluating progress towards Universal Health Coverage in Singapore. PLoS Med. 2014;11(9):e1001695. doi:10.1371/journal.pmed.1001695
11
The PLOS "monitoring universal health coverage" collection: managing expectations. PLoS Med. 2014;11(9):e1001732. doi:10.1371/journal.pmed.1001732
12
Gibbons L, Belizan JM, Lauer JA, Betran AP, Merialdi M, Althabe F. The global numbers and costs of additionally needed and unnecessary caesarean sections performed per year: overuse as a barrier to universal coverage. World Health Rep. 2010;30:1-31.
13
Boerma T, Eozenou P, Evans D, Evans T, Kieny MP, Wagstaff A. Monitoring progress towards universal health coverage at country and global levels. PLoS Med. 2014;11(9):e1001731. doi:10.1371/journal.pmed.1001731
14
Hosseinpoor AR, Bergen N, Koller T, et al. Equity-oriented monitoring in the context of universal health coverage. PLoS Med. 2014;11(9):e1001727. doi:10.1371/journal.pmed.1001727
15
Rodney AM, Hill PS. Achieving equity within universal health coverage: a narrative review of progress and resources for measuring success. Int J Equity Health. 2014;13:72. doi:10.1186/s12939-014-0072-8
16
Hanratty B, Zhang T, Whitehead M. How close have universal health systems come to achieving equity in use of curative services? A systematic review. Int J Health Serv. 2007;37(1):89-109. doi:10.2190/ttx2-3572-ul81-62w7
17
Valentine NB, Koller TS, Hosseinpoor AR. Monitoring health determinants with an equity focus: a key role in addressing social determinants, universal health coverage, and advancing the 2030 sustainable development agenda. Glob Health Action. 2016;9:34247. doi:10.3402/gha.v9.34247
18
WHO and World Bank. Tracking universal health coverage: 2017 Global Monitoring Report. Geneva: WHO and World Bank; 2017. http://www.worldbank.org/en/topic/universalhealthcoverage/publication/tracking-universal-health-coverage-2017-global-monitoring-report. Accessed July 30, 2018.
19
Buse K, Hawkes S. Health in the sustainable development goals: ready for a paradigm shift? Global Health. 2015;11:13. doi:10.1186/s12992-015-0098-8
20
Hosseinpoor AR, Bergen N, Schlotheuber A, Grove J. Measuring health inequalities in the context of sustainable development goals. Bull World Health Organ. 2018;96(9):654-659. doi:10.2471/blt.18.210401
21
Hosseinpoor AR, Bergen N. Health Inequality Monitoring: A Practical Application of Population Health Monitoring. In: Verschuuren M, van Oers H, eds. Population Health Monitoring: Climbing the Information Pyramid. Cham: Springer International Publishing; 2019:151-173. doi:10.1007/978-3-319-76562-4_8
22
Hosseinpoor AR, Bergen N, Magar V. Monitoring inequality: an emerging priority for health post-2015. Bull World Health Organ. 2015;93(9):591-591A. doi:10.2471/blt.15.162081
23
Baltussen R, Jansen MP, Bijlmakers L, Tromp N, Yamin AE, Norheim OF. Progressive realisation of universal health coverage: what are the required processes and evidence? BMJ Glob Health. 2017;2(3):e000342. doi:10.1136/bmjgh-2017-000342
24
Jannati A, Sadeghi V, Imani A, Saadati M. Effective coverage as a new approach to health system performance assessment: a scoping review. BMC Health Serv Res. 2018;18(1):886. doi:10.1186/s12913-018-3692-7
25
Stuckler D, Feigl AB, Basu S, McKee M. The political economy of universal health coverage. Montreux, Switzerland: Global Symposium on Health Systems Research; 2010.
26
ORIGINAL_ARTICLE
Cost-Effectiveness Analysis of Psoriasis Treatment Modalities in Malaysia
Background There is limited evidence detailing the cost-effectiveness of psoriasis treatments in the Asian region. Therefore, this study is aimed to evaluate the cost-effectiveness of 3 psoriasis treatments tailored for moderate to severe psoriasis, namely topical and phototherapy (TP), topical and systemic (TS), and topical and biologic (TB) regimens, respectively. Methods This has been achieved by the participation of a prospective cohort involving a total of 90 moderate to severe psoriasis patients, which has been conducted at 5 public hospitals in Malaysia. The main outcome measures have been evaluated via cost and effectiveness psoriasis area severity index (PASI)-75 and/or body surface area (BSA)
https://www.ijhpm.com/article_3607_0ff4b5f866b1c8a515c725f7d36992cd.pdf
2019-07-01
394
402
10.15171/ijhpm.2019.17
Cost-Effectiveness
Psoriasis
Phototherapy
Systemic
Biologic
Malaysia
Nor Azmaniza
Azizam
norazmaniza@gmail.com
1
Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia, Selangor, Malaysia
LEAD_AUTHOR
Aniza
Ismail
draniza@gmail.com
2
Department of Community Health, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
AUTHOR
Saperi
Sulong
saperi@ppukm.ukm.edu.my
3
Department of Community Health, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
AUTHOR
Norazirah Md
Nor
norazirah78@gmail.com
4
Medical Department, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
AUTHOR
Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70 (3):512-516. doi:10.1016/j.jaad.2013.11.013
1
Springate DA, Parisi R, Kontopantelis E, Reeves D, Griffiths CEM, Ashcroft DM. Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. Br J Dermatol. 2017;176 (3):650-658. doi:10.1111/bjd.15021
2
Ding X, Wang T, Shen Y, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012;22 (5):663-667. doi:10.1684/ejd.2012.1802
3
Mohd Affandi A, Ngah Saaya N, Johar A, Muneer A, Hamid A. Annual Report of the Malaysian Psoriasis Registry 2007-2015. Vol 13. Kuala Lumpur; 2017.
4
Thorleifsdottir R, Sigurdardottir S, Sigurgeirsson B, et al. Patient-reported outcomes and clinical response in patients with moderate-to-severe plaque psoriasis treated with tonsillectomy: a randomized controlled trial. Acta Derm Venereol. 2017:97(3):340-345. doi:10.2340/00015555-2562
5
Ministry of Health. Management of Psoriasis Vulgaris. Kuala Lumpur; 2013.
6
Carrascosa JM, Bonanad C, Dauden E, Botella R, Olveira-Martín A. Psoriasis and nonalcoholic fatty liver disease on behalf of the systemic inflammation in psoriasis working group. Actas Dermosifiliogr. 2017;108 (6):506-514.
7
Gisondi P, Cazzaniga S, Chimenti S, et al. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. J Eur Acad Dermatol Venereol. 2013;27(1):e30-e41. doi:10.1111/j.1468-3083.2012.04450.x
8
Shah K, Mellars L, Changolkar A, Feldman SR. Real-world burden of comorbidities in US patients with psoriasis. J Am Acad Dermatol. 2017;77(2):287-292.e4. doi:10.1016/j.jaad.2017.03.037
9
Singh S, Young P, Armstrong AW. An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies. PLoS One. 2017;12(7):e0181039. doi:10.1371/journal.pone.0181039
10
Vañó-Galván S, Gárate MT, Fleta-Asín B, et al. Analysis of the cost effectiveness of home-based phototherapy with narrow-band UV-B radiation compared with biological drugs for the treatment of moderate to severe psoriasis. Actas Dermosifiliogr. 2012;103(2):127-137. doi:10.1016/j.ad.2011.05.002
11
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2009;60(4):643-659. doi:10.1016/j.jaad.2008.12.032
12
Alfageme Roldán F, Bermejo Hernando A, Calvo González JL, Marqués Sánchez P. Cost Effectiveness of Treatments of Psoriasis with a PASI 75 and one Period of 12 Weeks. Rev Esp Salud Publica. 2016;90:E15.
13
Czarnecka-Operacz M, Sadowska-Przytocka A. The possibilities and principles of methotrexate treatment of psoriasis - the updated knowledge. Postepy Dermatol Alergol. 2014;31 (6):392-400. doi:10.5114/pdia.2014.47121
14
Oussedik E, Patel NU, Cash DR, Gupta AS, Feldman SR. Severe and acute complications of biologics in psoriasis. G Ital Dermatol Venereol. 2017;152(6):586-596. doi:10.23736/S0392-0488.17.05750-9
15
Mansouri Y, Goldenberg G. Biologic safety in psoriasis: Review of long-term safety data. J Clin Aesthet Dermatol. 2015;8(2):30-42.
16
Puig L, Julià A, Marsal S. The Pathogenesis and Genetics of Psoriasis. Actas Dermo-Sifiliográficas (English Ed). 2014;105(6):535-545. doi:10.1016/j.adengl.2014.05.013
17
Burgos-Pol R, Martínez-Sesmero JM, Ventura-Cerdá JM, Elías I, Caloto MT, Casado MÁ. Coste de la psoriasis y artritis psoriásica en cinco países de Europa: una revisión sistemática. Actas Dermosifiliogr. 2016;107 (7):577-590. doi:10.1016/j.ad.2016.04.018
18
Spandonaro F, Ayala F, Berardesca E, et al. The cost effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in Italy. BioDrugs. 2014;28 (3):285-295. doi:10.1007/s40259-014-0084-3
19
Korman NJ, Zhao Y, Pike J, Roberts J, Sullivan E. Increased severity of itching, pain, and scaling in psoriasis patients is associated with increased disease severity, reduced quality of life, and reduced work productivity. Dermatol Online J. 2015;21 (10).
20
Schmitt J, Küster D. Correlation between Dermatology Life Quality Index (DLQI) scores and Work Limitations Questionnaire (WLQ) allows the calculation of percent work productivity loss in patients with psoriasis. Arch Dermatol Res. 2015;307 (5):451-453. doi:10.1007/s00403-015-1567-x
21
Chan B, Hales B, Shear N, et al. Work-related lost productivity and its economic impact on Canadian patients with moderate to severe psoriasis. J Cutan Med Surg. 2009;13 (4):192-197.
22
Lewis-Beck C, Abouzaid S, Xie L, Baser O, Kim E. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Prefer Adherence. 2013;7:199-205. doi:10.2147/PPA.S39887
23
Li K, Armstrong AW. A review of health outcomes in patients with psoriasis. Dermatol Clin. 2012;30 (1):61-72. doi:10.1016/j.det.2011.08.012
24
Zhang W, Islam N, Ma C, Anis AH. Systematic review of cost-effectiveness analyses of treatments for psoriasis. Pharmacoeconomics. 2015;33(4):327-340. doi:10.1007/s40273-014-0244-9
25
Baker C, Mack A, Cooper A, et al. Treatment goals for moderate to severe psoriasis: an Australian consensus. Australas J Dermatol. 2013;54 (2):148-154. doi:10.1111/ajd.12014
26
Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303 (1):1-10. doi:10.1007/s00403-010-1080-1
27
Ministry Of Health. Surat Pekeliling Bil. 1 Tahun 2014 - Garis Panduan Pelaksanaan Perintah Fi (Perubatan) (Kos Perkhidmatan). http://www.moh.gov.my/index.php/database_stores/store_view_page/31/257. Published 2014. Accessed January 13, 2019.
28
Sulong S, Ismail A, Azizam NA, Md Nor N, Ahmed Z. Economic burden and cost effectiveness analysis of psoriasis treatment modalities in Malaysian public hospitals: a study protocol. In: The European Proceedings of Social & Behavioural Sciences. Vol 5. Future Academy; 2016:243-250. doi:10.15405/epsbs.2016.11.02.23
29
Küster D, Nast A, Gerdes S, et al. Cost-effectiveness of systemic treatments for moderate-to-severe psoriasis in the German health care setting. Arch Dermatol Res. 2016;308 (4):249-261. doi:10.1007/s00403-016-1634-y
30
D’Ausilio A, Aiello A, Daniel F, Graham C, Roccia A, Toumi M. A cost effectiveness analysis of secukinumab 300 MG vs current therapies for the treatment of moderate to severe plaque psoriasis in Italy. Value Heal. 2015;18:424.
31
Knight C, Mauskopf J, Ekelund M, Singh A, Yang S, Boggs R. {C}ost-effectiveness of treatment with etanercept for psoriasis in Sweden. Eur J Heal Econ. 2012;13 (2):145-156.
32
D’Souza LS, Payette MJ, Song M, Lim HW. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis. J Am Acad Dermatol. 2015;72 (4):589-598. doi:10.1016/j.jaad.2014.11.028
33
Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother. 2011;12 (13):2041-2054. doi:10.1517/14656566.2011.590475
34
Sizto S, Bansback N, Feldman SRR, Willian MKK, Anis AHH. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol. 2009;160 (6):1264-1272. doi:10.1111/j.1365-2133.2008.08962.x
35
Pearce DJ, Nelson AA, Fleischer AB, Balkrishnan R, Feldman SR. The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatolog Treat. 2006;17 (1):29-37. doi:10.1080/09546630500504754
36
Cabello Zurita C, Grau Pérez M, Hernández Fernández CP, et al. Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patients. J Dermatolog Treat. 2017;28 (5):401-405. doi:10.1080/09546634.2016.1273469
37
Knight C, Mauskopf J, Ekelund M, Singh A, Yang S, Boggs R. Cost-effectiveness of treatment with etanercept for psoriasis in Sweden. Eur J Heal Econ. 2012;13 (2):145-156. doi:10.1007/s10198-010-0293-8.
38
Verma S, Dharmarajan S, Yang Y. PSS12 modeling the cost-effectiveness of ustekinumab for moderate to severe plaque psoriasis in US. Value Heal. 2010;13 (3):A147. doi:10.1016/S1098-3015(10)72715-7.
39
Villacorta R, Hay JW, Messali A. Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States. Pharmacoeconomics. 2013;31 (9):823-839. doi:10.1007/s40273-013-0078-x
40
Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol. 2013;14 (4):315-326. doi:10.1007/s40257-013-0030-z
41
Salazar A, Aguirre A, Flores R. Cost-effectiveness analysis of ustekinumab for the treatment of adults with mild-to-moderate plaque psoriasis refractory to other biologic agents in Mexico. Value Heal. 2016;19 (3):A245. doi:10.1016/j.jval.2016.03.1046
42
Armstrong AW, Betts KA, Signorovitch JE, et al. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis. Curr Med Res Opin. 2018;34 (7):1325-1333. doi:10.1080/03007995.2018.1457516
43
de Argila D, Rodríguez-Nevado I, Chaves a. Cost-Effectiveness Analysis Comparing Methotrexate With PUVA Therapy for Moderate—Severe Psoriasis in the Sanitary Area of Badajoz. Actas Dermo-Sifiliográficas (English Ed). 2007;98 (1):35-41. doi:10.1016/S1578-2190 (07)70387-6
44
Colombo G, Altomare G, Peris K, et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag. 2008;4 (2):559-568.
45
Heinen-Kammerer T, Daniel D, Stratmann L, Rychlik R, Boehncke W-H. Cost-effectiveness of psoriasis therapy with etanercept in Germany. J Dtsch Dermatol Ges. 2007;5 (9):762-768. doi:10.1111/j.1610-0387.2007.06489.x
46
Johansson EC, Hartz S, Kiri SH, Kumar G, Svedbom A. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK. J Med Econ. June 2018:1-11. doi:10.1080/13696998.2018.1474747
47
Augustin M, McBride D, Gilloteau I, O’Neill C, Neidhardt K, Graham CN. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany. J Eur Acad Dermatology Venereol. 2018;32(12):2191-2199. doi:10.1111/jdv.15047
48
Klijn SL, van den Reek JMPA, van de Wetering G, van der Kolk A, de Jong EMGJ, Kievit W. Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE. Br J Dermatol. 2018;178 (5):1181-1189. doi:10.1111/bjd.16247
49
Igarashi A, Kuwabara H, Fahrbach K, Schenkel B. Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan. J Dermatolog Treat. 2013;24 (5):351-355. doi:10.3109/09546634.2012.697111
50
Pan F, Brazier NC, Shear NH, Jivraj F, Schenkel B, Brown R. Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective. Value Health. 2011;14 (5):652-656. doi:10.1016/j.jval.2011.01.006
51
Bronsard V, Paul C, Prey S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatology Venereol. 2010;24:17-22. doi:10.1111/j.1468-3083.2009.03563.x
52
Hägg D, Sundström A, Eriksson M, Schmitt-Egenolf M. Severity of psoriasis differs between men and women: a study of the clinical outcome measure psoriasis area and severity index (PASI) in 5438 Swedish register patients. Am J Clin Dermatol. 2017;18 (4):583-590. doi:10.1007/s40257-017-0274-0
53
Riveros BS, Ziegelmann PK, Correr CJ. Cost-effectiveness of biologic agents in the treatment of moderate-to-severe psoriasis: a Brazilian public health service perspective. Value Heal Reg Issues. 2014;5:65-72. doi:10.1016/j.vhri.2014.09.002
54
Cohen S, Baron S, Archer C, British Association of Dermatologists and Royal College of General Practitioners. Guidance on the diagnosis and clinical management of psoriasis. Clin Exp Dermatol. 2012;37 Suppl 1:13-18. doi:10.1111/j.1365-2230.2012.04337.x
55
Walsh JA, McFadden M, Woodcock J, et al. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol. 2013;69 (6):931-937. doi:10.1016/j.jaad.2013.07.040
56
Mattei PLL, Corey KCC, Kimball ABB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28 (3):333-337. doi:10.1111/jdv.12106
57
Blome C, Beikert FC, Rustenbach SJ, Augustin M. Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities. Arch Dermatol Res. 2013;305 (3):197-204. doi:10.1007/s00403-012-1309-2
58
Herédi E, Rencz F, Balogh O, et al. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. Eur J Heal Econ. 2014;15 (S1):111-119. doi:10.1007/s10198-014-0600-x
59
Driessen RJB, Bisschops LA, Adang EMM, Evers AW, Van De Kerkhof PCM, De Jong EMGJ. The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. Br J Dermatol. 2010;162 (6):1324-1329. doi:10.1111/j.1365-2133.2010.09693.x
60
Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol. 2010;146 (1):46-54. doi:10.1001/archdermatol.2009.319
61
ORIGINAL_ARTICLE
Understanding Health Professional Responses to Service Disinvestment: A Qualitative Study
Background Disinvestment from inefficient health services may be a potential solution to rising healthcare costs, but there has been poor uptake of disinvestment recommendations. This Australian study aims to understand how health professionals react when confronted with a plan to disinvest from a health service they previously provided to their patients. Methods This qualitative study took place prior to the disinvestment phase of a trial which removed weekend allied health services from acute hospital wards, to evaluate the effectiveness and cost effectiveness of the service. Observations and focus groups were used to collect data from 156 participants which was analysed thematically. Results Initial reactions to the disinvestment were almost universally negative, with staff extremely concerned about the impact on the safety and quality of patient care and planning ways to circumvent the trial. Removal of existing services was perceived as a loss and created a direct threat to some clinicians’ professional identity. With time, discussion, and understanding of the project’s context, some staff moved towards acceptance and perceived the trial as an opportunity, particularly given the service was to be reinstated after the disinvestment. Conclusion Clinicians and health service managers are protective of the services they deliver and can create barriers to disinvestment. Even when services are removed to ascertain their value, health professionals may continue to provide services to their patients. Measuring the impact of the disinvestment may assist staff to accept the removal of a service.
https://www.ijhpm.com/article_3610_26797f3fa8a81fc6feb9bb7242d7eb11.pdf
2019-07-01
403
411
10.15171/ijhpm.2019.20
Disinvestment
Staff Reactions
Weekend Allied Health Services
Service Change
Healthcare
Deb
Mitchell
debra.mitchell@monash.edu
1
Monash Health Community, Monash Health, Dandenong, VIC, Australia
LEAD_AUTHOR
Lisa
O’Brien
lisa.o.brien@monash.edu
2
Occupational Therapy Department, School of Primary and Allied Health Care, Monash University, Frankston, VIC, Australia
AUTHOR
Anne
Bardoel
abardoel@swin.edu.au
3
Department of Management and Marketing, Swinburne University of Technology, Hawthorn, VIC, Australia
AUTHOR
Terry
Haines
terrence.haines@monash.edu
4
School of Primary and Allied Health Care, Monash University, Frankston, VIC, Australia
AUTHOR
Keehan SP, Cuckler GA, Sisko AM, et al. National health expenditure projections, 2014-24: spending growth faster than recent trends. Health Aff (Millwood). 2015;34(8):1407-1417. doi:10.1377/hlthaff.2015.0600
1
Elshaug AG, Hiller JE, Tunis SR, Moss JR. Challenges in Australian policy processes for disinvestment from existing, ineffective health care practices. Aust New Zealand Health Policy. 2007;4:23. doi:10.1186/1743-8462-4-23
2
Fineberg HV. Shattuck Lecture. A successful and sustainable health system--how to get there from here. N Engl J Med. 2012;366(11):1020-1027. doi:10.1056/NEJMsa1114777
3
Elshaug AG, Hiller JE, Moss JR. Exploring policy-makers' perspectives on disinvestment from ineffective healthcare practices. Int J Technol Assess Health Care. 2008;24(1):1-9. doi:10.1017/s0266462307080014
4
Rooshenas L, Owen-Smith A, Hollingworth W, Badrinath P, Beynon C, Donovan JL. "I won't call it rationing...": an ethnographic study of healthcare disinvestment in theory and practice. Soc Sci Med. 2015;128:273-281. doi:10.1016/j.socscimed.2015.01.020
5
Garner S, Littlejohns P. Disinvestment from low value clinical interventions: NICEly done? BMJ. 2011;343:d4519. doi:10.1136/bmj.d4519
6
Rosenberg A, Agiro A, Gottlieb M, et al. Early trends among seven recommendations from the Choosing Wisely campaign. JAMA Intern Med. 2015;175(12):1913-1920. doi:10.1001/jamainternmed.2015.5441
7
Daniels T, Williams I, Robinson S, Spence K. Tackling disinvestment in health care services. The views of resource allocators in the English NHS. J Health Organ Manag. 2013;27(6):762-780. doi:10.1108/jhom-11-2012-0225
8
Harlock J, Williams I, Robert G, Hall K, Mannion R, Brearley S. Doing more with less in health care: findings from a multi-method study of decommissioning in the English National Health Service. J Soc Policy. 2018;47(3):543-564. doi:10.1017/s0047279417000721
9
Daniels T, Williams I, Bryan S, Mitton C, Robinson S. Involving citizens in disinvestment decisions: what do health professionals think? Findings from a multi-method study in the English NHS. Health Econ Policy Law. 2018;13(2):162-188. doi:10.1017/s1744133117000330
10
Shoolin JS. Change management - recommendations for successful electronic medical records implementation. Appl Clin Inform. 2010;1(3):286-292. doi:10.4338/aci-2010-01-r-0001
11
Hewitt-Taylor J. Planning successful change incorporating processes and people. Nurs Stand. 2013;27(38):35-40. doi:10.7748/ns2013.05.27.38.35.e7560
12
Daugird A, Spencer D. Physician reactions to the health care revolution. A grief model approach. Arch Fam Med. 1996;5(9):497-500. doi:10.1001/archfami.5.9.497
13
Haines TP, O'Brien L, Mitchell D, et al. Study protocol for two randomized controlled trials examining the effectiveness and safety of current weekend allied health services and a new stakeholder-driven model for acute medical/surgical patients versus no weekend allied health services. Trials. 2015;16:133. doi:10.1186/s13063-015-0619-z
14
Shaw KD, Taylor NF, Brusco NK. Physiotherapy services provided outside of business hours in Australian hospitals: a national survey. Physiother Res Int. 2013;18(2):115-123. doi:10.1002/pri.1537
15
Campbell L, Bunston R, Colangelo S, et al. The provision of weekend physiotherapy services in tertiary-care hospitals in Canada. Physiother Can. 2010;62(4):347-354. doi:10.3138/physio.62.4.347
16
Mitchell D, O'Brien L, Bardoel A, Haines T. Challenges, uncertainties and perceived benefits of providing weekend allied health services-a managers' perspective. BMC Health Serv Res. 2017;17(1):118. doi:10.1186/s12913-017-2035-4
17
Brusco NK, Shields N, Taylor NF, Paratz J. A Saturday physiotherapy service may decrease length of stay in patients undergoing rehabilitation in hospital: a randomised controlled trial. Aust J Physiother. 2007;53(2):75-81. doi:10.1016/s0004-9514(07)70039-9
18
DiSotto-Monastero M, Chen X, Fisch S, Donaghy S, Gomez M. Efficacy of 7 days per week inpatient admissions and rehabilitation therapy. Arch Phys Med Rehabil. 2012;93(12):2165-2169. doi:10.1016/j.apmr.2012.07.003
19
Peiris CL, Shields N, Brusco NK, Watts JJ, Taylor NF. Additional Saturday rehabilitation improves functional independence and quality of life and reduces length of stay: a randomized controlled trial. BMC Med. 2013;11:198. doi:10.1186/1741-7015-11-198
20
Haines T, O'Brien L, McDermott F, et al. A novel research design can aid disinvestment from existing health technologies with uncertain effectiveness, cost-effectiveness, and/or safety. J Clin Epidemiol. 2014;67(2):144-151. doi:10.1016/j.jclinepi.2013.08.014
21
Haines TP, Bowles KA, Mitchell D, et al. Impact of disinvestment from weekend allied health services across acute medical and surgical wards: 2 stepped-wedge cluster randomised controlled trials. PLoS Med. 2017;14(10):e1002412. doi:10.1371/journal.pmed.1002412
22
Wicks AC, Freeman RE. Organization studies and the new pragmatism: Positivism, anti-positivism, and the search for ethics. Organ Sci. 1998;9(2):123-140. doi:10.1287/orsc.9.2.123
23
Braun V, Clarke V. What can "thematic analysis" offer health and wellbeing researchers? Int J Qual Stud Health Well-being. 2014;9:26152. doi:10.3402/qhw.v9.26152
24
Kubler-Ross E. On death and dying: What the dying have to teach doctors, nurses, clergy and their own families. Taylor & Francis; 2009.
25
Dziadzko MA, Herasevich V, Sen A, Pickering BW, Knight AM, Moreno Franco P. User perception and experience of the introduction of a novel critical care patient viewer in the ICU setting. Int J Med Inform. 2016;88:86-91. doi:10.1016/j.ijmedinf.2016.01.011
26
Conroy SA, O'Leary-Kelly AM. Letting go and moving on: Work-related identity loss and recovery. Acad Manage Rev. 2014;39(1):67-87. doi:10.5465/amr.2011.0396
27
Saario S. Managerial reforms and specialised psychiatric care: a study of resistive practices performed by mental health practitioners. Sociol Health Illn. 2012;34(6):896-910. doi:10.1111/j.1467-9566.2011.01439.x
28
Goss ME. Influence and authority among physicians in an outpatient clinic. Am Sociol Rev. 1961;26(1):39-50. doi:10.2307/2090511
29
Henderson-Loney J. Tuckman and tears: developing teams during profound organizational change. Supervision. 1996;57(5):3-5.
30
Wiggins L. Managing the ups and downs of change communication. Strategic Communication Management. 2008;13(1):20.
31
Airoldi M. Disinvestments in practice: overcoming resistance to change through a sociotechnical approach with local stakeholders. J Health Polit Policy Law. 2013;38(6):1149-1171. doi:10.1215/03616878-2373175
32
Elshaug AG, Watt AM, Mundy L, Willis CD. Over 150 potentially low‐value health care practices: an Australian study. Med J Aust. 2012;197(10):556-560. doi:10.5694/mja12.11083
33
ORIGINAL_ARTICLE
Development of the Translating Allied Health Knowledge (TAHK) Framework
Background While evidence-based practice is a familiar concept to allied health clinicians, knowledge translation (KT) is less well known and understood. The need for a framework that enables allied health clinicians to access and engage with KT was identified. The aim of this paper is to describe the development of the Translating Allied Health Knowledge (TAHK) Framework. Methods An iterative and collaborative process involving clinician and academic knowledge partners was utilised to develop the TAHK Framework. Multiple methods were utilised during this process, including a systematic literature review, steering committee consultation, mixed methods survey, benchmarking and measurement property analysis. Results The TAHK Framework has now been finalised, and is described in detail. The framework is structured around four domains – Doing Knowledge Translation, Social Capital for Knowledge Translation, Sustaining Knowledge Translation and Inclusive Knowledge Translation – under which 14 factors known to influence allied health KT are classified. The formulation of the framework to date has laid a rigorous foundation for further developments, including clinician support and outcome measurement. Conclusion The method of development adopted for the TAHK Framework has ensured it is both evidence and practice based, and further amendments and modifications are anticipated as new knowledge becomes available. The Framework will enable allied health clinicians to build on their existing capacities for KT, and approach this complex process in a rigorous and systematic manner. The TAHK Framework offers a unique focus on how knowledge is translated by allied health clinicians in multidisciplinary settings.
https://www.ijhpm.com/article_3614_4a02650394ce29825f00362ee93faef4.pdf
2019-07-01
412
423
10.15171/ijhpm.2019.23
Allied Health Occupations
Allied Health Personnel
Knowledge Translation
Implementation Science
Knowledge Exchange
Danielle
Hitch
dani.hitch@deakin.edu.au
1
Occupational Therapy, Health & Social Development, Deakin University, Geelong, VIC, Australia
LEAD_AUTHOR
Genevieve
Pepin
genevieve.pepin@deakin.edu.au
2
Occupational Therapy, Health & Social Development, Deakin University, Geelong, VIC, Australia
AUTHOR
Kate
Lhuede
kate.lhuede@mh.org.au
3
Occupational Therapy, North West Mental Health, Melbourne, VIC, Australia
AUTHOR
Sue
Rowan
suero@barwonhealth.org.au
4
Occupational Therapy, Barwon Health, Geelong, VIC, Australia
AUTHOR
Susan
Giles
susan.giles@wh.org.au
5
Occupational Therapy, Western Health, Melbourne, VIC, Australia
AUTHOR
Department of Health. Review of Australian government health workforce programs. Canberra: Australian Government, Department of Health; 2013.
1
Donini-Lenhoff FG. Coming together, moving apart: a history of the term allied health in education, accreditation, and practice. J Allied Health. 2008;37(1):45-52.
2
Allied Health Professions Australia (AHPA). Allied Health Professions 2018. https://ahpa.com.au/allied-health-professions/.
3
Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312(7023):71-72.
4
Glasziou PP, Del Mar C, Salisbury J. Evidence-based medicine workbook. Malden, MA: John Wiley & Sons; 2009.
5
Nevo I, Slonim-Nevo V. The myth of evidence-based practice: Towards evidence-informed practice. Br J Soc Work. 2011;41(6):1176-1197. doi:10.1093/bjsw/bcq149
6
Grimmer-Somers K, Lekkas P, Nyland L, Young A, Kumar S. Perspectives on research evidence and clinical practice: a survey of Australian physiotherapists. Physiother Res Int. 2007;12(3):147-161. doi:10.1002/pri.363
7
Harding KE, Porter J, Horne-Thompson A, Donley E, Taylor NF. Not enough time or a low priority? Barriers to evidence-based practice for allied health clinicians. J Contin Educ Health Prof. 2014;34(4):224-231. doi:10.1002/chp.21255
8
Hoffman LM, Ireland M, Hall-Mills S, Flynn P. Evidence-based speech-language pathology practices in schools: findings from a national survey. Lang Speech Hear Serv Sch. 2013;44(3):266-280. doi:10.1044/0161-1461(2013/12-0041)
9
Callender L, Brown R, Driver S, Dahdah M, Collinsworth A, Shafi S. Process for developing rehabilitation practice recommendations for individuals with traumatic brain injury. BMC Neurol. 2017;17(1):54. doi:10.1186/s12883-017-0828-z
10
Verloo H, Desmedt M, Morin D. Beliefs and implementation of evidence-based practice among nurses and allied healthcare providers in the Valais hospital, Switzerland. J Eval Clin Pract. 2017;23(1):139-148. doi:10.1111/jep.12653
11
Bucknall T, Hitch D. Connections, Communication and Collaboration in Healthcare's Complex Adaptive Systems Comment on "Using Complexity and Network Concepts to Inform Healthcare Knowledge Translation". Int J Health Policy Manag. 2017;7(6):556-559. doi:10.15171/ijhpm.2017.138
12
Straus SE, Tetroe J, Graham I. Defining knowledge translation. CMAJ. 2009;181(3-4):165-168. doi:10.1503/cmaj.081229
13
Atack L, Luke R. Impact of an online course on infection control and prevention competencies. J Adv Nurs. 2008;63(2):175-180. doi:10.1111/j.1365-2648.2008.04660.x
14
Lokker C, McKibbon KA, Wilczynski NL, et al. Finding knowledge translation articles in CINAHL. Stud Health Technol Inform. 2010;160(Pt 2):1179-1183.
15
Wright N. First-time knowledge brokers in health care: the experiences of nurses and allied health professionals of bridging the research-practice gap. Evid Policy. 2013;9(4):557-570. doi:10.1332/174426413X13836462527470
16
Hitch D, Rowan S, Nicola-Richmond K. A case study of knowledge brokerage in occupational therapy. Int J Ther Rehabil. 2014;21(8):389-396. doi:10.12968/ijtr.2014.21.8.389
17
Gupta S, Moosa D, MacPherson A, Allen C, Tamari IE. Effects of a 12-month multi-faceted mentoring intervention on knowledge, quality, and usage of spirometry in primary care: a before-and-after study. BMC Pulm Med. 2016;16(1):56. doi:10.1186/s12890-016-0220-6
18
Atwal A, Spiliotopoulou G. Knowledge transfer: developing guidelines for occupational therapists working with people with lower limb amputations. Br J Occup Ther. 2011;74(3):109. doi:10.4276/030802211x12996065859120
19
Moodie ST, Kothari A, Bagatto MP, Seewald R, Miller LT, Scollie SD. Knowledge translation in audiology: promoting the clinical application of best evidence. Trends Amplif. 2011;15(1):5-22. doi:10.1177/1084713811420740
20
Brosseau L, Wells GA, Tugwell P, et al. Ottawa Panel evidence-based clinical practice guidelines for the management of osteoarthritis in adults who are obese or overweight. Phys Ther. 2011;91(6):843-861. doi:10.2522/ptj.20100104
21
Warner G. Synthesizing research evidence for therapists providing home-based rehabilitative care. Phys Occup Ther Geriatr. 2013;31(2):115-127. doi:10.3109/02703181.2013.771296
22
Kredo T, Bernhardsson S, Machingaidze S, et al. Guide to clinical practice guidelines: the current state of play. Int J Qual Health Care. 2016;28(1):122-128. doi:10.1093/intqhc/mzv115
23
Moore JL, Raad J, Ehrlich-Jones L, Heinemann AW. Development and use of a knowledge translation tool: the rehabilitation measures database. Arch Phys Med Rehabil. 2014;95(1):197-202. doi:10.1016/j.apmr.2013.09.010
24
Archambault PM, Bilodeau A, Gagnon MP, et al. Health care professionals' beliefs about using wiki-based reminders to promote best practices in trauma care. J Med Internet Res. 2012;14(2):e49. doi:10.2196/jmir.1983
25
Bowden FM, Lordly D, Thirsk J, Corby L. Phase II Practice-based Evidence in Nutrition (PEN) evaluation: interviews with key informants. Can J Diet Pract Res. 2012;73(1):e233-240. doi:10.3148/73.1.2012.e233
26
Doran D, Paterson J, Clark C, et al. A pilot study of an electronic interprofessional evidence-based care planning tool for clients with mental health problems and addictions. Worldviews Evid Based Nurs. 2010;7(3):174-184. doi:10.1111/j.1741-6787.2010.00191.x
27
Campbell L, Novak I, McIntyre S, Lord S. A KT intervention including the evidence alert system to improve clinician's evidence-based practice behavior--a cluster randomized controlled trial. Implement Sci. 2013;8:132. doi:10.1186/1748-5908-8-132
28
Scott SD, Albrecht L, O'Leary K, et al. Systematic review of knowledge translation strategies in the allied health professions. Implement Sci. 2012;7:70. doi:10.1186/1748-5908-7-70
29
Imms C, Kerr C, Novak I, et al. Knowledge translation for allied health professionals working with children with cerebral palsy: effects on evidence-based knowledge and practice. Physiotherapy. 2016;102(Suppl 1):e35-36. doi:10.1016/j.physio.2016.10.049
30
Haines TP, Waldron NG. Translation of falls prevention knowledge into action in hospitals: what should be translated and how should it be done? J Safety Res. 2011;42(6):431-442. doi:10.1016/j.jsr.2011.10.003
31
Girard A, Rochette A, Fillion B. Knowledge translation and improving practices in neurological rehabilitation: managers' viewpoint. J Eval Clin Pract. 2013;19(1):60-67. doi:10.1111/j.1365-2753.2011.01769.x
32
Nilsen P. Making sense of implementation theories, models and frameworks. Implement Sci. 2015;10:53. doi:10.1186/s13012-015-0242-0
33
Smith M, Wilkinson H, Gallagher M. ‘It's what gets through people's radars isn't it’: relationships in social work practice and knowledge exchange. Contemp Soc Sci. 2013;8(3):292-306. doi:10.1080/21582041.2012.751499
34
Forhan M, Law M. An evaluation of a workshop about obesity designed for occupational therapists. Can J Occup Ther. 2009;76(5):351-358. doi:10.1177/000841740907600506
35
Birken SA, Powell BJ, Shea CM, et al. Criteria for selecting implementation science theories and frameworks: results from an international survey. Implement Sci. 2017;12(1):124. doi:10.1186/s13012-017-0656-y
36
Greenhalgh T. Knowledge to action: there is no tooth fairy. https://www.cebm.net/2015/11/knowledge-to-action-there-is-no-tooth-fairy/ . Published September 19, 2018.
37
Squires JE, Graham ID, Hutchinson AM, et al. Understanding context in knowledge translation: a concept analysis study protocol. J Adv Nurs. 2015;71(5):1146-1155. doi:10.1111/jan.12574
38
Pain T, Kingston G, Askern J, Smith R, Phillips S, Bell L. How are allied health notes used for inpatient care and clinical decision-making? A qualitative exploration of the views of doctors, nurses and allied health professionals. Health Inf Manag. 2017;46(1):23-31. doi:10.1177/1833358316664451
39
Dorning H, Bardsley MNI. “focus on AHPs”: Quality Watch Health Foundation; 2014. http://www.nuffieldtrust.org.uk/publications/focus-allied-health-professionals.
40
Buchan J, Law D. A review of allied health workforce models and structures: A report to the Victorian Ministerial Advisory Committee for Allied Health. Melbourne: Victorian Government; 2016.
41
Raven M. Allied health practitioners in Australian primary health care. Adelaide: Primary Health Care Research & Information Service; 2014.
42
Moore GF, Audrey S, Barker M, et al. Process evaluation of complex interventions: Medical Research Council guidance. BMJ. 2015;350:h1258. doi:10.1136/bmj.h1258
43
Campbell M, Fitzpatrick R, Haines A, et al. Framework for design and evaluation of complex interventions to improve health. BMJ. 2000;321(7262):694-696.
44
Burns KD, Wolfs W, Belanger P, McLaughlin K, Levin A. The KRESCENT Program: an initiative to match supply and demand for kidney research in Canada. Clin Invest Med. 2010;33(6):E356-367.
45
Lane H, Sturgess T, Philip K, et al. What factors do allied health take into account when making resource allocation decisions? Int J Health Policy Manag. 2017;7(5):412-420. doi:10.15171/ijhpm.2017.105
46
Pawson R, Tilley N. Realistic evaluation. Thousand Oaks, CA, US: Sage; 1997.
47
Slade SC, Philip K, Morris ME. Frameworks for embedding a research culture in allied health practice: a rapid review. Health Res Policy Syst. 2018;16(1):1-15. doi:10.1186/s12961-018-0304-2
48
Schofield T. Gendered organizational dynamics: the elephant in the room for Australian allied health workforce policy and planning? J Sociol. 2009;45(4):383-400. doi:10.1177/1440783309346479
49
Turnbull C, Grimmer-Somers K, Kumar S, May E, Law D, Ashworth E. Allied, scientific and complementary health professionals: a new model for Australian allied health. Aust Health Rev. 2009;33(1):27-37.
50
Boyce RA. Organisational governance structures in allied health services: a decade of change. Aust Health Rev. 2001;24(1):22-36.
51
Rowe PA, Boyce RA, Boyle MV, O'Reilly K. A comparative analysis of entrepreneurial approaches within public healthcare organisations. Aust J Public Adm. 2004;63(2):16-30. doi:10.1111/j.1467-8500.2004.00375.x
52
Metzler MJ, Metz GA. Translating knowledge to practice: an occupational therapy perspective. Aust Occup Ther J. 2010;57(6):373-379. doi:10.1111/j.1440-1630.2010.00873.x
53
Thigpen S, Puddy RW, Singer HH, Hall DM. Moving knowledge into action: developing the rapid synthesis and translation process within the interactive systems framework. Am J Community Psychol. 2012;50(3-4):285-294. doi:10.1007/s10464-012-9537-3
54
Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322-1327.
55
Jack S, Tonmyr L. Knowledge transfer and exchange: disseminating Canadian child maltreatment surveillance findings to decision makers. Child Indic Res. 2008;1(1):51-64. doi:10.1007/s12187-007-9001-3
56
Lavis J, Ross S, McLeod C, Gildiner A. Measuring the impact of health research. J Health Serv Res Policy. 2003;8(3):165-170. doi:10.1258/135581903322029520
57
Ask LN. Rogaland County Council and Universal Design. Stud Health Technol Inform. 2016;229:78-84.
58
Adam P, Ovseiko PV, Grant J, et al. ISRIA statement: ten-point guidelines for an effective process of research impact assessment. Health Res Policy Syst. 2018;16(1):8. doi:10.1186/s12961-018-0281-5
59
Hitch D, Pepin G, Stagnitti K. The pan occupational paradigm: development and key concepts. Scand J Occup Ther. 2018;25(1):27-34. doi:10.1080/11038128.2017.1337808
60
Pennell KG, Thompson M, Rice JW, Senier L, Brown P, Suuberg E. Bridging research and environmental regulatory processes: the role of knowledge brokers. Environ Sci Technol. 2013;47(21):11985-11992. doi:10.1021/es4025244
61
Kothari A, McCutcheon C, Graham ID. Defining integrated knowledge translation and moving forward: a response to recent commentaries. Int J Health Policy Manag. 2017;6(5):299-300. doi:10.15171/ijhpm.2017.15
62
Nahapiet J, Ghoshal S. Social capital, intellectual capital, and the organizational advantage. Acad Manage Rev. 1998;23(2):242-266. doi:10.2307/259373
63
Kislov R, Wilson P, Boaden R. The 'dark side' of knowledge brokering. J Health Serv Res Policy. 2017;22(2):107-112. doi:10.1177/1355819616653981
64
Hakkennes S, Dodd K. Guideline implementation in allied health professions: a systematic review of the literature. Qual Saf Health Care. 2008;17(4):296-300. doi:10.1136/qshc.2007.023804
65
Hall AE, Bryant J, Sanson-Fisher RW, Fradgley EA, Proietto AM, Roos I. Consumer input into health care: Time for a new active and comprehensive model of consumer involvement. Health Expect. 2018;21(4):707-713. doi:10.1111/hex.12665
66
McArthur A, Klugarova J, Yan H, Florescu S. Innovations in the systematic review of text and opinion. Int J Evid Based Healthc. 2015;13(3):188-195. doi:10.1097/xeb.0000000000000060
67
Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467-473. doi:10.7326/m18-0850
68
Cramm H, Short B, Donnelly CA. Knowledge translation and occupational therapy: A survey of Canadian university programs. Open J Occup Ther. 2016;4(4):1-11. doi:10.15453/2168-6408.1196
69
Alison JA, Zafiropoulos B, Heard R. Key factors influencing allied health research capacity in a large Australian metropolitan health district. J Multidiscip Healthc. 2017;10:277-291. doi:10.2147/jmdh.s142009
70
Campbell L, Novak I, McIntyre S, Lord S. A KT intervention including the evidence alert system to improve clinician's evidence-based practice behavior--a cluster randomized controlled trial. Implement Sci. 2013;8:132. doi:10.1186/1748-5908-8-132
71
Hadouda S, Laroui HR, Lemay A, et al. Practice style traits of student occupational therapists and physical therapists. Can J Occup Ther. 2009;76(2):98-106. doi:10.1177/000841740907600207
72
Novak I, Russell D, Ketelaar M. What works in knowledge translation: A systematic review. Adelaide: OT Australia Conference; 2013.
73
Bradd P, Travaglia J, Hayen A. Allied health leadership in New South Wales: a study of perceptions and priorities of allied health leaders. Aust Health Rev. 2018;42(3):316-320. doi:10.1071/ah16135
74
Hitch D, Lhuede K, Vernon L, Pepin G, Stagnitti K. Longitudinal evaluation of a knowledge translation role in occupational therapy. Knowledge Utilisation Colloquium; November 8-10, 2017; Melbourne, Australia.
75
McCluskey A, Middleton S. Delivering an evidence-based outdoor journey intervention to people with stroke: barriers and enablers experienced by community rehabilitation teams. BMC Health Serv Res. 2010;10:18. doi:10.1186/1472-6963-10-18
76
Bennett S, Whitehead M, Eames S, Fleming J, Low S, Caldwell E. Building capacity for knowledge translation in occupational therapy: learning through participatory action research. BMC Med Educ. 2016;16(1):257. doi:10.1186/s12909-016-0771-5
77
Dawes M, Summerskill W, Glasziou P, et al. Sicily statement on evidence-based practice. BMC Med Educ. 2005;5(1):1. doi:10.1186/1472-6920-5-1
78
Graham ID, Logan J, Harrison MB, et al. Lost in knowledge translation: time for a map? J Contin Educ Health Prof. 2006;26(1):13-24. doi:10.1002/chp.47
79
Green G. Power to the people: to what extent has public involvement in applied health research achieved this? Research Involvement and Engagement. 2016;2(1):1-13. doi:10.1186/s40900-016-0042-y
80
Kitson A, Brook A, Harvey G, et al. Using Complexity and Network Concepts to Inform Healthcare Knowledge Translation. Int J Health Policy Manag. 2017;7(3):231-243. doi:10.15171/ijhpm.2017.79
81
Leach K, Hitch D, Neale S. Evaluating the implementation of an Early Stroke Discharge (ESD) program at Western Health: Preliminary Report. Melbourne: Western Health; 2017.
82
Perry L, Grange A, Heyman B, Noble P. Stakeholders' perceptions of a research capacity development project for nurses, midwives and allied health professionals. J Nurs Manag. 2008;16(3):315-326. doi:10.1111/j.1365-2834.2007.00801.x
83
Mickan S, Wenke R, Weir K, Bialocerkowski A, Noble C. Strategies for research engagement of clinicians in allied health (STRETCH): a mixed methods research protocol. BMJ Open. 2017;7(9):e014876. doi:10.1136/bmjopen-2016-014876
84
Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50. doi:10.1186/1748-5908-4-50
85
Kitson A, Harvey G, McCormack B. Enabling the implementation of evidence based practice: a conceptual framework. Qual Health Care. 1998;7(3):149-158.
86
ORIGINAL_ARTICLE
Moving Towards Accountability for Reasonableness – A Systematic Exploration of the Features of Legitimate Healthcare Coverage Decision-Making Processes Using Rare Diseases and Regenerative Therapies as a Case Study
Background The accountability for reasonableness (A4R) framework defines 4 conditions for legitimate healthcare coverage decision processes: Relevance, Publicity, Appeals, and Enforcement. The aim of this study was to reflect on how the diverse features of decision-making processes can be aligned with A4R conditions to guide decision-making towards legitimacy. Rare disease and regenerative therapies (RDRTs) pose special decision-making challenges and offer therefore a useful case study. Methods Features operationalizing each A4R condition as well as three different approaches to address these features (cost-per-QALY-focused and multicriteria-based) were defined and organized into a matrix. Seven experts explored these features during a panel run under the Chatham House Rule and provided general and RDRT-specific recommendations. Responses were analyzed to identify converging and diverging recommendations. Results Regarding Relevance, recommendations included supporting deliberation, stakeholder participation and grounding coverage decision criteria in normative and societal objectives. Thirteen of 17 proposed decision criteria were recommended by a majority of panelists. The usefulness of universal cost-effectiveness thresholds to inform allocative efficiency was challenged, particularly in the RDRT context. RDRTs raise specific issues that need to be considered; however, rarity should be viewed in relation to other aspects, such as disease severity and budget impact. Regarding Publicity, panelists recommended transparency about the values underlying a decision and value judgements used in selecting evidence. For Appeals, recommendations included a life-cycle approach with clear provisions for re-evaluations. For Enforcement, external quality reviews of decisions were recommended. Conclusions Moving coverage decision-making processes towards enhanced legitimacy in general and in the RDRT context involves designing and refining approaches to support participation and deliberation, enhancing transparency, and allowing explicit consideration of multiple decision criteria that reflect normative and societal objectives.
https://www.ijhpm.com/article_3615_8f58488bba29cb46b19af5cffb1e2ead.pdf
2019-07-01
424
443
10.15171/ijhpm.2019.24
Accountability for Reasonableness
Rare Diseases
Multicriteria Decision Analysis
Cost-Effectiveness Analysis
Monika
Wagner
mtinwagner@yahoo.ca
1
Analytica Laser, Montreal, QC, Canada
LEAD_AUTHOR
Dima
Samaha
d.samaha@analytica-laser.com
2
Analytica Laser, London, UK
AUTHOR
Roman
Casciano
r.casciano@analytica-laser.com
3
Analytica Laser, New York City, NY, USA
AUTHOR
Matthew
Brougham
m.brougham@analytica-laser.com
4
Analytica Laser, Montreal, QC, Canada
AUTHOR
Payam
Abrishami
pabrishami@zinl.nl
5
National Health Care Institute (ZIN), Diemen, The Netherlands
AUTHOR
Charles
Petrie
chasdpetrie@gmail.com
6
Pfizer Inc, New York City, NY, USA (retired)
AUTHOR
Bernard
Avouac
avouacb@gmail.com
7
Liège University, Liège, Belgium
AUTHOR
Lorenzo
Mantovani
lorenzo.mantovani@unimib.it
8
Center for Public Health Research, University of Milan-Bicocca, Milan, Italy
AUTHOR
Antonio
Sarría-Santamera
asarria@isciii.es
9
National School of Public Health IMIENS-UNED, Madrid, Spain
AUTHOR
Paul
Kind
p.kind@leeds.ac.uk
10
University of Leeds, Leeds, UK
AUTHOR
Michael
Schlander
m.schlander@dkfz.de
11
Division of Health Economics, German Cancer Research Center (DKFZ), Heidelberg, Germany
AUTHOR
Michele
Tringali
michele_tringali@regione.lombardia.it
12
ASST Niguarda and Regione Lombardia, Welfare Directorate, Milano, Italy
AUTHOR
Definition of legitimacy in English by Oxford Dictionaries. English Oxford Dictionary website. https://en.oxforddictionaries.com/definition/legitimacy. Updated 2018.
1
Terwindt F, Rajan D, Soucat A. Priority-setting for national health policies, strategies and plans. In: Strategizing national health in the 21st century: a handbook. World Health Organization; 2016.
2
Clark S, Weale A. Social values in health priority setting: a conceptual framework. J Health Organ Manag. 2012;26(3):293-316. doi:10.1108/14777261211238954
3
Daniels N. Justice, health, and healthcare. Am J Bioeth. 2001;1(2):2-16. doi:10.1162/152651601300168834
4
Goetghebeur M, Castro-Jaramillo H, Baltussen R, Daniels N. The art of priority setting. Lancet. 2017;389(10087):2368-2369. doi:10.1016/s0140-6736(17)31573-8
5
Daniels N. Decisions about access to health care and accountability for reasonableness. J Urban Health. 1999;76(2):176-191. doi:10.1007/bf02344674
6
Daniels N. Accountability for reasonableness. BMJ. 2000;321(7272):1300-1301.
7
Daniels N, van der Wilt GJ. Health technology assessment, deliberative process, and ethically contested issues. Int J Technol Assess Health Care. 2016;32(1-2):10-15. doi:10.1017/s0266462316000155
8
Daniels N, Sabin J. Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers. Philos Public Aff. 1997;26(4):303-350.
9
Hasman A, Holm S. Accountability for reasonableness: opening the black box of process. Health Care Anal. 2005;13(4):261-273. doi:10.1007/s10728-005-8124-2
10
Badano G. If You're a Rawlsian, How Come You're So Close to Utilitarianism and Intuitionism? A Critique of Daniels's Accountability for Reasonableness. Health Care Anal. 2018;26(1):1-16. doi:10.1007/s10728-017-0343-9
11
Friedman A. Beyond accountability for reasonableness. Bioethics. 2008;22(2):101-112. doi:10.1111/j.1467-8519.2007.00605.x
12
Daniels N, Porteny T, Urritia J. Expanded HTA: enhancing fairness and legitimacy. Int J Health Policy Manag. 2015;5(1):1-3. doi:10.15171/ijhpm.2015.187
13
Baltussen R, Jansen MPM, Bijlmakers L, et al. Value assessment frameworks for HTA agencies: the organization of evidence-informed deliberative processes. Value Health. 2017;20(2):256-260. doi:10.1016/j.jval.2016.11.019
14
Culyer AJ. Ethics, priorities and cancer. J Cancer Policy. 2017;11:6-11. doi:10.1016/j.jcpo.2016.09.007
15
National Institute for Health and Care Excellence. NICE Process [PMG9]. Guide to the methods of technology appraisal 2013. National Institute for Health and Care Excellence website. http://nice.org.uk/process/pmg9. Updated 2013. Accessed August 14, 2016.
16
Gold MR, Stevenson D, Fryback DG. HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population Health. Annu Rev Public Health. 2002;23:115-134. doi:10.1146/annurev.publhealth.23.100901.140513
17
Angelis A, Kanavos P. Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework. Soc Sci Med. 2017;188:137-156. doi:10.1016/j.socscimed.2017.06.024
18
Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Evidence and Value: Impact on DEcisionMaking--the EVIDEM framework and potential applications. BMC Health Serv Res. 2008;8:270. doi:10.1186/1472-6963-8-270
19
Radaelli G, Lettieri E, Masella C, Merlino L, Strada A, Tringali M. Implementation of EUnetHTA core Model(R) in Lombardia: the VTS framework. Int J Technol Assess Health Care. 2014;30(1):105-112. doi:10.1017/s0266462313000639
20
Youngkong S, Baltussen R, Tantivess S, Mohara A, Teerawattananon Y. Multicriteria decision analysis for including health interventions in the universal health coverage benefit package in Thailand. Value Health. 2012;15(6):961-970. doi:10.1016/j.jval.2012.06.006
21
Regier DA, Peacock S. Theoretical foundations of MCDA. In: Marsh K, Goetghebeur M, Thokala P, Baltussen R, eds. Multi-Criteria Decision Analysis to Support Healthcare Decisions. Switzerland: Springer International Publishing; 2017:9-28.
22
Paulden M, Stafinski T, Menon D, McCabe C. Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework. Pharmacoeconomics. 2015;33(3):255-269. doi:10.1007/s40273-014-0235-x
23
Phelps CE, Madhavan G. Using multicriteria approaches to assess the value of health care. Value Health. 2017;20(2):251-255. doi:10.1016/j.jval.2016.11.011
24
Wagner M, Khoury H, Willet J, Rindress D, Goetghebeur M. Can the EVIDEM framework tackle issues raised by evaluating treatments for rare diseases: analysis of issues and policies, and context-specific adaptation. Pharmacoeconomics. 2016;34(3):285-301. doi:10.1007/s40273-015-0340-5
25
Mitton CR, McMahon M, Morgan S, Gibson J. Centralized drug review processes: are they fair? Soc Sci Med. 2006;63(1):200-211. doi:10.1016/j.socscimed.2005.11.049
26
Jansson S. Implementing accountability for reasonableness--the case of pharmaceutical reimbursement in Sweden. Health Econ Policy Law. 2007;2(Pt 2):153-171. doi:10.1017/s1744133107004082
27
Schlander M. NICE accountability for reasonableness: a qualitative study of its appraisal of treatments for attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin. 2007;23(1):207-222. doi:10.1185/030079906x159461
28
Schlander M. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no (t yet an) exemplar of a deliberative process. J Med Ethics. 2008;34(7):534-539. doi:10.1136/jme.2007.021683
29
Greenberg D, Siebzehner MI, Pliskin JS. The process of updating the National List of Health Services in Israel: is it legitimate? Is it fair? Int J Technol Assess Health Care. 2009;25(3):255-261. doi:10.1017/s026646230999016x
30
Goetghebeur M, Wagner M. Identifying value (s): a reflection on the ethical aspects of MCDA in healthcare decisionmaking. In: Marsh K, Goetghebeur M, Thokala P, Baltussen R, eds. Multi-Criteria Decision Analysis to Support Healthcare Decisions. Switzerland: Springer International Publishing; 2017:29-46.
31
Berwick DM, Nolan TW, Whittington J. The triple aim: care, health, and cost. Health Aff (Millwood). 2008;27(3):759-769. doi:10.1377/hlthaff.27.3.759
32
Drummond M, Towse A. Orphan drugs policies: a suitable case for treatment. Eur J Health Econ. 2014;15(4):335-340. doi:10.1007/s10198-014-0560-1
33
Gericke CA, Riesberg A, Busse R. Ethical issues in funding orphan drug research and development. J Med Ethics. 2005;31(3):164-168. doi:10.1136/jme.2003.007138
34
Mahalatchimy A. Reimbursement of cell-based regenerative therapy in the UK and France. Med Law Rev. 2016;24(2):234-258. doi:10.1093/medlaw/fww009
35
Corbett MS, Webster A, Hawkins R, Woolacott N. Innovative regenerative medicines in the EU: a better future in evidence? BMC Med. 2017;15(1):49. doi:10.1186/s12916-017-0818-4
36
Nicod E. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries. Eur J Health Econ. 2017;18(6):715-730. doi:10.1007/s10198-016-0823-0
37
Daniels N, Sabin EJ. Setting limits fairly: Learning to Share Resources for Health. 2nd ed. New York: Oxford University Press; 2008.
38
Sandman L, Gustavsson E. Beyond the Black Box Approach to Ethics! Comment on "Expanded HTA: Enhancing Fairness and Legitimacy." Int J Health Policy Manag. 2016;5(6):393-394. doi:10.15171/ijhpm.2016.43
39
Abrishami P, Oortwijn W, Hofmann B. Ethics in HTA: Examining the "Need for Expansion." Int J Health Policy Manag. 2017;6(10):551-553. doi:10.15171/ijhpm.2017.43
40
Culyer AJ. HTA - Algorithm or Process? Comment on "Expanded HTA: Enhancing Fairness and Legitimacy." Int J Health Policy Manag. 2016;5(8):501-505. doi:10.15171/ijhpm.2016.59
41
Oortwijn W, Determann D, Schiffers K, Tan SS, van der Tuin J. Towards integrated health technology assessment for improving decision making in selected countries. Value Health. 2017;20(8):1121-1130. doi:10.1016/j.jval.2017.03.011
42
European Commission. Process on Corporate Social Responsibility in the Field of Pharmaceuticals Platform on Access to Medicines in Europe Working Group on Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA-OMP). Transparent Value Framework; 2014.
43
Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7:74. doi:10.1186/1750-1172-7-74
44
Iskrov G, Miteva-Katrandzhieva T, Stefanov R. Multi-criteria decision analysis for assessment and appraisal of orphan drugs. Front Public Health. 2016;4:214. doi:10.3389/fpubh.2016.00214
45
Kolasa K, Zwolinski KM, Kalo Z, Hermanowski T. Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs. Orphanet J Rare Dis. 2016;11:23. doi:10.1186/s13023-016-0388-0
46
Sussex J, Rollet P, Garau M, Schmitt C, Kent A, Hutchings A. A pilot study of multicriteria decision analysis for valuing orphan medicines. Value Health. 2013;16(8):1163-1169. doi:10.1016/j.jval.2013.10.002
47
Schlander M, Garattini S, Holm S, et al. Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. J Comp Eff Res. 2014;3(4):399-422. doi:10.2217/cer.14.34
48
Nord E. Beyond QALYs: Multi-criteria based estimation of maximum willingness to pay for health technologies. Eur J Health Econ. 2018;19(2):267-275. doi:10.1007/s10198-017-0882-x
49
National Institute for Health and Care Excellence (NICE). Interim process and methods of the highly specialised technologies programme. Updated to reflect 2017 changes. National Institute for Health and Care Excellence website. https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-highly-specialised-technologies-guidance. Updated 2017. Accessed May 24, 2017.
50
National Institute for Health and Care Excellence (NICE). NICE and NHS England consultation on changes to the arrangements for evaluating and funding drugs and other health technologies assessed through NICE's technology appraisal and highly specialised technologies programmes. National Institute for Health and Care Excellence website. https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/consultation-on-changes-to-technology-appraisals-and-highly-specialised-technologies. Updated 2017. Accessed May 24, 2017.
51
Scottish Medicines Consortium (SMC). SMC modifiers used in appraising new medicines. SMC website. https://www.scottishmedicines.org.uk/About_SMC/Policy_statements/SMC_Modifiers_used_in_Appraising_New_Medicines. Updated 2017. Accessed April 13, 2017.
52
Scottish Medicines Consortium (SMC). PACE (Patient & Clinician Engagement) overview document. SMC website. https://www.scottishmedicines.org.uk/Submission_Process/Submission_guidance_and_forms/PACE. Updated 2016. Accessed May 10, 2017.
53
Hettle R, Corbett M, Hinde S, et al. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. Health Technol Assess. 2017;21(7):1-204. doi:10.3310/hta21070
54
Thokala P, Devlin N, Marsh K, et al. Multiple criteria decision analysis for health care decision making--an introduction: report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016;19(1):1-13. doi:10.1016/j.jval.2015.12.003
55
Marsh K, M IJ, Thokala P, et al. Multiple criteria decision analysis for health care decision making--emerging good practices: report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016;19(2):125-137. doi:10.1016/j.jval.2015.12.016
56
Frenk J. The global health system: strengthening national health systems as the next step for global progress. PLoS Med. 2010;7(1):e1000089. doi:10.1371/journal.pmed.1000089
57
Ronfard V, Vertes AA, May MH, Dupraz A, van Dyke ME, Bayon Y. Evaluating the past, present, and future of regenerative medicine: a global view. Tissue Eng Part B Rev. 2017;23(2):199-210. doi:10.1089/ten.TEB.2016.0291
58
Buckland KF, Bobby Gaspar H. Gene and cell therapy for children--new medicines, new challenges? Adv Drug Deliv Rev. 2014;73:162-169. doi:10.1016/j.addr.2014.02.010
59
Royal Institute of International Affairs. Chatham House Rule. Royal Institute of International Affairs website. https://www.chathamhouse.org/about/chatham-house-rule. Updated 2002. Accessed September 15, 2015.
60
Schlander M, Telser H, Holm S, Marshall D, Nord E, Richardson J. The European Social Preference Measurement (ESPM) study: Conceptual considerations and implementation. Poster presented at: ISPOR 19th Annual European Congress; Oct 29-Nov 2, 2016; Vienna, Austria.
61
Tanios N, Wagner M, Tony M, et al. Which criteria are considered in healthcare decisions? Insights from an international survey of policy and clinical decision makers. Int J Technol Assess Health Care. 2013;29(4):456-465. doi:10.1017/s0266462313000573
62
Lakdawalla DN, Doshi JA, Garrison LP Jr, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care--a health economics approach: an ISPOR Special Task Force report [3]. Value Health. 2018;21(2):131-139. doi:10.1016/j.jval.2017.12.007
63
Annemans L, Ayme S, Le Cam Y, et al. Recommendations from the European working Group for Value Assessment and Funding Processes in rare diseases (ORPH-VAL). Orphanet J Rare Dis. 2017;12(1):50. doi:10.1186/s13023-017-0601-9
64
EURORDIS. Breaking the access deadlock to leave no one behind. EURORDIS website. http://download.eurordis.org.s3.amazonaws.com/positionpapers/eurordis_access_position_paper_final_4122017.pdf. Updated 2018. Accessed December 18, 2017.
65
Nicod E, Kanavos P. Scientific and social value judgments for orphan drugs in health technology assessment. Int J Technol Assess Health Care. 2016;32(4):218-232. doi:10.1017/s0266462316000416
66
Silva EN, Sousa TR. Economic evaluation in the context of rare diseases: is it possible? Cad Saude Publica. 2015;31(3):496-506.
67
Bertram MY, Lauer JA, De Joncheere K, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94(12):925-930. doi:10.2471/blt.15.164418
68
Birch S, Gafni A. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold. J Health Serv Res Policy. 2006;11(1):46-51. doi:10.1258/135581906775094235
69
Schlander M, Dintsios CM, Gandjour A. Budgetary impact and cost drivers of drugs for rare and ultrarare diseases. Value Health. 2018;21(5):525-531. doi:10.1016/j.jval.2017.10.015
70
Schuller Y, Hollak CE, Biegstraaten M. The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review. Orphanet J Rare Dis. 2015;10:92. doi:10.1186/s13023-015-0305-y
71
Drummond M, Knies S, Garau M. Sustainable funding and fair pricing for orphan drugs: what are the solutions? Presented at: ISPOR 20th Annual European Congress; 2017 Nov 4-8. Glasgow, Scotland.
72
Linley WG, Hughes DA. Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain. Health Econ. 2013;22(8):948-964. doi:10.1002/hec.2872
73
Wiss J, Levin LA, Andersson D, Tinghog G. Prioritizing rare diseases: psychological effects influencing medical decision making. Med Decis Making. 2017;37(5):567-576. doi:10.1177/0272989x17691744
74
Desser AS, Gyrd-Hansen D, Olsen JA, Grepperud S, Kristiansen IS. Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67. BMJ. 2010;341:c4715. doi:10.1136/bmj.c4715
75
Dragojlovic N, Rizzardo S, Bansback N, Mitton C, Marra CA, Lynd LD. Challenges in measuring the societal value of orphan drugs: insights from a Canadian stated preference survey. Patient. 2015;8(1):93-101. doi:10.1007/s40271-014-0109-5
76
Mentzakis E, Stefanowska P, Hurley J. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study. Health Econ Policy Law. 2011;6(3):405-433. doi:10.1017/s1744133110000344
77
Desser AS. Prioritizing treatment of rare diseases: a survey of preferences of Norwegian doctors. Soc Sci Med. 2013;94:56-62. doi:10.1016/j.socscimed.2013.06.019
78
EURORDIS. Rare diseases: Understanding this public health priority. EURORDIS website. http://www.eurordis.org/publication/rare-diseases-understanding-public-health-priority. Updated 2005. Accessed October 21, 2013.
79
Abelson J, Wagner F, DeJean D, et al. Public and patient involvement in health technology assessment: a framework for action. Int J Technol Assess Health Care. 2016;32(4):256-264. doi:10.1017/s0266462316000362
80
Gagnon MP, Desmartis M, Lepage-Savary D, et al. Introducing patients' and the public's perspectives to health technology assessment: A systematic review of international experiences. Int J Technol Assess Health Care. 2011;27(1):31-42. doi:10.1017/s0266462310001315
81
Rowe G, Frewer LJ. A typology of public engagement mechanisms. Sci Technol Human Values. 2005;30(2):251-290. doi:10.1177/0162243904271724
82
Douglas CM, Wilcox E, Burgess M, Lynd LD. Why orphan drug coverage reimbursement decision-making needs patient and public involvement. Health Policy. 2015;119(5):588-596. doi:10.1016/j.healthpol.2015.01.009
83
Facey K, Granados A, Guyatt G, et al. Generating health technology assessment evidence for rare diseases. Int J Technol Assess Health Care. 2014;30(4):416-422. doi:10.1017/s0266462314000464
84
Menon D, Stafinski T, Dunn A, Wong-Rieger D. Developing a patient-directed policy framework for managing orphan and ultra-orphan drugs throughout their lifecycle. Patient. 2015;8(1):103-117. doi:10.1007/s40271-014-0108-6
85
Youngkong S, Teerawattananon Y, Tantivess S, Baltussen R. Multi-criteria decision analysis for setting priorities on HIV/AIDS interventions in Thailand. Health Res Policy Syst. 2012;10:6. doi:10.1186/1478-4505-10-6
86
Goetghebeur MM, Wagner M, Khoury H, Rindress D, Gregoire JP, Deal C. Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients. Cost Eff Resour Alloc. 2010;8:4. doi:10.1186/1478-7547-8-4
87
Wagner M, Khoury H, Bennetts L, et al. Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA. BMC Cancer. 2017;17(1):272. doi:10.1186/s12885-017-3258-9
88
Christiaens W, Kohn L, Leonard C, Denis A, Daue F, Cleemput I, et al. Models for citizen and patient involvement in health care policy: Part I: Exploration of their feasibility and acceptability. Brussels: Belgian Health Care Knowledge Centre; 2012.
89
Abrishami Shirazi P, Boer A, Horstman K. Value in co-creation: Subjecting innovative in-hospital technologies to multi-stakeholder appraisal. International Journal of Hospital Based Health Technology Assessment. 2017;1:12-30. doi:10.21965/IJHBHTA.2017.002
90
Hofmann B, Cleemput I, Bond K, et al. Revealing and acknowledging value judgments in health technology assessment. Int J Technol Assess Health Care. 2014;30(6):579-586. doi:10.1017/s0266462314000671
91
ORIGINAL_ARTICLE
The Need for a Dynamic Approach to Health System-Centered Innovations; Comment on “What Health System Challenges Should Responsible Innovation in Health Address? Insights From an International Scoping Review”
Lehoux and colleagues plea for a health systems perspective to evaluate innovations. Since many innovations and their scale-up strategies emerge from processes that are not (centrally) steered, we plea for any assessment with a dynamic, instead of a sequential, approach. We provide further guidance on how to adopt such dynamic approach, in order to better un-derstand and steer innovations for better health systems. A systems-level challenge is constituted by interactions and feedback loops between different actors and components of the health system. It is therefore essential to explore both the entry-point of innovation and the interactions with other components. If innovation is regarded as an injection of resources and opportunities into a health system, this system needs to have the capacity to transform these into desired outputs, the ‘absorption capacity.’ The highly organic diffusion of innovation in complex adapative systems cannot be easily controlled, but the system behaviours can be analysed, with occurance of phenomena such as path dependence, feedback loops, scale-free networks, emergent behaviour and phase transitions. This helps to anticipate unintended consequences, and to engage key actors in ongoing problem-solving and adaptation. By adopting a prospective approach, responsible innovation could set in motion prospective policy evaluations, which on the basis of iterative learning would allow decisionmakers to continuously adapt their policies and programmes. Priority-setting for innovation is an essentially political process that is geared towards consensus-building and grounded in values.
https://www.ijhpm.com/article_3622_e9bf04e14554097193a47fadaaa84f6c.pdf
2019-07-01
444
446
10.15171/ijhpm.2019.25
Health Systems
Health Systems Agency
Diffusion of Innovation
Josefien
van Olmen
josefien.vanolmen@uantwerpen.be
1
Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium
LEAD_AUTHOR
Bruno
Marchal
bmarchal@itg.be
2
Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium
AUTHOR
Button
Ricarte
buttonricarte@gmail.com
3
Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium
AUTHOR
Wim
Van Damme
wvandamme@itg.be
4
Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium
AUTHOR
Sara
Van Belle
svanbelle@itg.be
5
Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium
AUTHOR
Donabedian A. Evaluating the quality of medical care. 1966. Milbank Q. 2005;83(4):691-729. doi:10.1111/j.1468-0009.2005.00397.x
1
van Olmen J, Criel B, Bhojani U, et al. The health system dynamics framework: the introduction of an analytical model for health system analysis and its application to two case-studies. Health Cult Soc. 2012;2(1):1-21. doi:10.5195/hcs.2012.71
2
Lehoux P, Roncarolo F, Silva HP, Boivin A, Denis J-L, Hebert R. What health system challenges should responsible innovation in health address? Insights from an international scoping review. Int J Health Policy Manag. 2019;8(2):63-75. doi:10.15171/ijhpm.2018.110
3
Greenhalgh T, Robert G, Macfarlane F, Bate P, Kyriakidou O. Diffusion of innovations in service organizations: systematic review and recommendations. Milbank Q. 2004;82(4):581-629. doi:10.1111/j.0887-378X.2004.00325.x
4
de Savigny D, Blanchet K, Adam T. Applied systems thinking for health systems research: a methodological handbook. Open University Press; 2017.
5
van Olmen J, Criel B, Van Damme W, et al. Analysing health system dynamics. (Studies in Health Services Organization & Policy). Report No.: 28. Antwerp: ITGPress; 2012.
6
Atun R, de Jongh T, Secci F, Ohiri K, Adeyi O. A systematic review of the evidence on integration of targeted health interventions into health systems. Health Policy Plan. 2010;25(1):1-14. doi:10.1093/heapol/czp053
7
Potter C, Brough R. Systemic capacity building: a hierarchy of needs. Health Policy Plan. 2004;19(5):336-345.
8
Paina L, Peters DH. Understanding pathways for scaling up health services through the lens of complex adaptive systems. Health Policy Plan. 2012;27(5):365-373. doi:10.1093/heapol/czr054
9
Pacifico Silva H, Lehoux P, Miller FA, Denis JL. Introducing responsible innovation in health: a policy-oriented framework. Health Res Policy Syst. 2018;16(1):1-13. doi:10.1186/s12961-018-0362-5
10
Cairney P. Complexity theory in political science and public policy. Political Stud. Rev. 2012;10(3):346-358. doi:10.1111/j.1478-9302.2012.00270.x
11
Geyer R, Rahani S. Complexity and Public Policy. Complexity and Public Policy; 2014.
12
Edelenbos J, van Meerkerk I, van Leeuwen C. Vitality of complex water governance systems: Condition and evolution. Journal of Environmental Policy & Planning. 2015;17(2):237-261. doi:10.1080/1523908X.2014.936584
13
Klijn EH, Koppenjan JFM. Complexity in governance network theory. Complexity, Governance & Networks. 2014;1(1):61-70. doi:10.7564/14-CGN8
14
Room G. Complexity, institutions and public policy: Agile decision-making in a turbulent world. Cheltenham: Edward Elgar; 2011.
15
Pierre J, Peters BG. Governance without government? Rethinking public administration. J Public Adm Res Theory. 1998;8(2):223-243.
16
Pelletier D, Gervais S, Hafeez-Ur-Rehman H, Sanou D, Tumwine J. Boundary-spanning actors in complex adaptive governance systems: The case of multisectoral nutrition. Int J Health Plann Manage. 2018;33(1):e293-e319. doi:10.1002/hpm.2468
17
Van Lerberghe W, Mechbal A, Kronfol N. The Collaborative Governance of Lebanon’s Health Sector: Twenty Years of Efforts to Transform Health System Performance. Policy Support Observatory; 2018.
18
Daniels N. Accountability for reasonableness. BMJ. 2000;321(7272):1300-1301.
19
Daniels N, Sabin JE. Setting limits fairly: can we learn to share medical resources? Oxford Scholarship Online; 2009:1-206.
20
ORIGINAL_ARTICLE
Who is Responsible for Responsible Innovation? Lessons From an Investigation into Responsible Innovation in Health; Comment on “What Health System Challenges Should Responsible Innovation in Health Address? Insights From an International Scoping Review”
Responsible innovation in health (RIH) takes the ideas of responsible research and innovation (RRI) and applies them to the health sector. This comment takes its point of departure from Lehoux et al which describes a structured literature review to determine the system-level challenges that health systems in countries at different levels of human development face. This approach offers interesting insights from the perspective of RRI, but it also raises the question whether and how RRI can be steered and achieved across healthcare systems. This includes the question who, if anybody, is responsible for responsible innovation and which insights can be drawn from the systemic nature RIH.
https://www.ijhpm.com/article_3619_bb1720be59662b5d36eee0e13e2e6d9c.pdf
2019-07-01
447
449
10.15171/ijhpm.2019.32
Responsible Innovation
Responsible Research and Innovation
Responsible Innovation in Health
Bernd Carsten
Stahl
bstahl@dmu.ac.uk
1
De Montfort University, Leicester, UK
LEAD_AUTHOR
Brey PAE, Soraker J. Philosophy of computing and information technology. In: Gabbay DM, Meijers AWM, Woods J, Thagard P, eds. Philosophy of technology and engineering sciences. Amsterdam: Elsevier; 2009:1341-1408. doi:10.1016/B978-0-444-51667-1.50051-3
1
Bynum TW. The historical roots of information and computer ethics. In: Floridi L, ed. The Cambridge handbook of information and computer ethics. Cambridge: Cambridge University Press; 2010:20-38. doi:10.1017/CBO9780511845239.003
2
Coenen C, Simakova E. STS policy interactions, technology assessment and the governance of technovisionary sciences. Science Technology and Innovation Studies. 2013;9(2):3-20.
3
Doherty NF, Coombs CR, Loan-Clarke J. A re-conceptualization of the interpretive flexibility of information technologies: redressing the balance between the social and the technical. Eur J Inf Syst. 2006;15(6):569-582. doi:10.1057/palgrave.ejis.3000653
4
Grunwald A. Responsible innovation: bringing together technology assessment, applied ethics, and STS research. Enterprise and Work Innovation Studies. 2011;7:9-31.
5
Hackett EJ, Amsterdamska O, Lynch ME, Wajcman J. The handbook of science and technology studies. 3rd ed. Cambridge, Mass: MIT Press; 2007.
6
Lehoux P, Roncarolo F, Silva HP, Boivin A, Denis JL, Hebert R. What health system challenges should responsible innovation in health address? Insights from an international scoping review. Int J Health Policy Manag. 2019;8(2):63-75. doi:10.15171/ijhpm.2018.110
7
Moor JH. What is computer ethics? Metaphilosophy. 1985;16(4):266-275. doi:10.1111/j.1467-9973.1985.tb00173.x
8
Oudshoorn N, Rommes E, Stienstra M. Configuring the user as everybody: Gender and design cultures in information and communication technologies. Sci Technol Human Values. 2004;29(1):30-63. doi:10.1177/0162243903259190
9
Owen R, Heintz M, Bessant J. Responsible Innovation. Chichester, West Sussex, UK: Wiley; 2013.
10
Stahl BC. Responsible research and innovation: The role of privacy in an emerging framework. Sci Public Policy. 2013;40(6):708-716. doi:10.1093/scipol/sct067
11
Stahl BC, Timmermans J, Rainey S, Shaw M. Ethics in innovation management as meta-responsibility: The practice of responsible research and innovation in human brain simulation. In: Chen J, Brem A, Viardot E, Wong PK, eds. The routledge companion to innovation management. New York: Routledge; 2019:435-454.
12
Timmermans J, Yaghmaei E, Stahl BC, Brem A. Research and innovation processes revisited–networked responsibility in industry. Sustainability Accounting, Management and Policy Journal. 2017;8(3):307-334. doi:10.1108/SAMPJ-04-2015-0023
13
Von Schomberg R. Towards responsible research and innovation in the information and communication technologies and security technologies fields. Luxembourg: Publication Office of the European Union; 2011. doi:10.2139/ssrn.2436399
14
Williams LDA, Woodson TS. Enhancing Socio-technical Governance: Targeting Inequality in Innovation Through Inclusivity Mainstreaming. Minerva. 2019;1-25. doi:10.1007/s11024-019-09375-4
15
ORIGINAL_ARTICLE
“Big” Food, Tobacco, and Alcohol: Reducing Industry Influence on Noncommunicable Disease Prevention Laws and Policies; Comment on “Addressing NCDs: Challenges From Industry Market Promotion and Interferences”
The food, tobacco and alcohol industries have penetrated markets in low- and middle-income countries (LMICs), with a significant impact on these countries’ burden of noncommunicable diseases (NCDs). Tangcharoensathien and colleagues describe the aggressive marketing of unhealthy food, alcohol and tobacco in LMICs, as well as key tactics used by these industries to resist laws and policies designed to reduce behavioural risk factors for NCDs. This commentary expands on the recommendations made by Tangcharoensathien and colleagues for preventing or managing conflicts of interest and reducing undue industry influence on NCD prevention policies and laws, focusing on the needs of LMICs. A growing body of research proposes ways to design voluntary industry initiatives to make them more effective, transparent and accountable, but governments should also consider whether collaboration with health-harming industries is ever appropriate. More fundamentally, mechanisms for identifying, managing and mitigating conflicts of interest and reducing industry influence must be woven into – and supported by – broader governance and regulatory structures at both national and international levels.
https://www.ijhpm.com/article_3618_c564dcc8827ed25e973d231d294abfa4.pdf
2019-07-01
450
454
10.15171/ijhpm.2019.30
Conflicts of Interest
Noncommunicable Disease
Law
Policy
Industry Influence
Belinda
Reeve
belinda.reeve@gmail.com
1
The University of Sydney Law School, Sydney, NSW, Australia
LEAD_AUTHOR
Lawrence O.
Gostin
gostin@law.georgetown.edu
2
O’Neill Institute for National and Global Health Law, Georgetown University Law Center, Washington, DC, USA
AUTHOR
Bollyky TJ, Templin T, Cohen M, Dieleman JL. Lower-income countries that face the most rapid shift in noncommunicable disease burden are also the least prepared. Health Aff (Millwood). 2017;36(11):1866-1875. doi:10.1377/hlthaff.2017.0708
1
Moodie R, Stuckler D, Monteiro C, et al. Profits and pandemics: prevention of harmful effects of tobacco, alcohol, and ultra-processed food and drink industries. Lancet. 2013;381(9867):670-679. doi:10.1016/s0140-6736(12)62089-3
2
Stuckler D, McKee M, Ebrahim S, Basu S. Manufacturing epidemics: the role of global producers in increased consumption of unhealthy commodities including processed foods, alcohol, and tobacco. PLoS Med. 2012;9(6):e1001235. doi:10.1371/journal.pmed.1001235
3
Tangcharoensathien V, Chandrasiri O, Kunpeuk W, Markchang K, Pangkariya N. Addressing NCDs: challenges from industry market promotion and interference. Int J Health Policy Manag. 2019;8(5):256-260. doi:10.15171/ijhpm.2019.02
4
Sustainable development goal 3: Ensure healthy lives and promote well-being for all at all ages. United Nationswebsite. https://sustainabledevelopment.un.org/sdg3. Accessed May 6, 2019.
5
World Cancer Research Fund. Building momentum: lessons on implementing a robust sugar sweetened beverage tax. https://www.wcrf.org/sites/default/files/PPA-Building-Momentum-Report-WEB.pdf. Published 2018.
6
Gostin LO, Monahan JT, Kaldor J, et al. The legal determinants of health: harnessing the power of law for global health and sustainable development. Lancet. 2019;393(10183):1857-1910. doi:10.1016/s0140-6736(19)30233-8
7
World Health Organisation (WHO). Advancing the right to health: the vital role of law. Geneva: WHO; 2017.
8
Magnusson RS, McGrady B, Gostin L, Patterson D, Abou Taleb H. Legal capacities required for prevention and control of noncommunicable diseases. Bull World Health Organ. 2019;97(2):108-117. doi:10.2471/blt.18.213777
9
Buse K, Tanaka S, Hawkes S. Healthy people and healthy profits? Elaborating a conceptual framework for governing the commercial determinants of non-communicable diseases and identifying options for reducing risk exposure. Global Health. 2017;13(1):34. doi:10.1186/s12992-017-0255-3
10
McKee M, Stuckler D. Revisiting the corporate and commercial determinants of health. Am J Public Health. 2018;108(9):1167-1170. doi:10.2105/ajph.2018.304510
11
Wiist W. The corporate playbook, health, and democracy. In: Stuckler D, Siegel K, eds. Sick Societies: Responding to the Global Challenge of Chronic Disease. New York: Oxford University Press; 2011:204-216.
12
Delobelle P, Sanders D, Puoane T, Freudenberg N. Reducing the role of the food, tobacco, and alcohol industries in noncommunicable disease risk in South Africa. Health Educ Behav. 2016;43(1 Suppl):70s-81s. doi:10.1177/1090198115610568
13
Greenhalgh S. Soda industry influence on obesity science and policy in China. J Public Health Policy. 2019;40(1):5-16. doi:10.1057/s41271-018-00158-x
14
World Health Organisation (WHO). WHO Framework Convention on Tobacco Control. Geneva: WHO; 2003.
15
Knai C, Petticrew M, Douglas N, et al. The public health responsibility deal: Using a systems-level analysis to understand the lack of impact on alcohol, food, physical activity, and workplace health sub-systems. Int J Environ Res Public Health. 2018;15(12). doi:10.3390/ijerph15122895
16
Stuckler D, Nestle M. Big food, food systems, and global health. PLoS Med. 2012;9(6):e1001242. doi:10.1371/journal.pmed.1001242
17
World Health Organisation (WHO). Draft approach on the prevention and management of conflicts of interest in the policy development and implementation of nutrition programmes at country level. Decision-Making Process and Tool. Geneva: WHO; 2017. https://www.who.int/nutrition/consultation-doi/comments/en/.
18
Barbor TF, Caetano R, Casswell S, et al. Alcohol: No Ordinary Commodity: Research and Public Policy. 2nd ed. New York: Oxford University Press; 2010.
19
Anderson P. Global alcohol policy and the alcohol industry. Curr Opin Psychiatry. 2009;22(3):253-257. doi:10.1097/YCO.0b013e328329ed75
20
Kraak VI, Swinburn B, Lawrence M, Harrison P. An accountability framework to promote healthy food environments. Public Health Nutr. 2014;17(11):2467-2483. doi:10.1017/s1368980014000093
21
Reeve B, Magnusson R. Reprint of: Food reformulation and the (neo)-liberal state: new strategies for strengthening voluntary salt reduction programs in the UK and USA. Public Health. 2015;129(8):1061-1073. doi:10.1016/j.puhe.2015.04.021
22
Reeve B. Self-regulation of food advertising to children: an effective tool for improving the food marketing environment? Monash Univ Law Rev. 2016;42(2):419-457.
23
Magnusson RS. Framework legislation for non-communicable diseases: and for the Sustainable Development Goals? BMJ Glob Health. 2017;2(3):e000385. doi:10.1136/bmjgh-2017-000385
24
Ayres I, Braithwaite J. Responsive Regulation: Transcending the Deregulation Debate. New York: Oxford University Press; 1995.
25
Baker P, Jones A, Thow AM. Accelerating the worldwide adoption of sugar-sweetened beverage taxes: strengthening commitment and capacity: Comment on "the untapped power of soda taxes: incentivizing consumers, generating revenue, and altering corporate behaviour." Int J Health Policy Manag. 2017;7(5):474-478. doi:10.15171/ijhpm.2017.127
26
Statement by Michael R. Bloomberg on Philip Morris International v. Uruguay Decision. Mike Bloomberg website. https://www.mikebloomberg.com/news/statement-by-michael-r-bloomberg-on-philip-morris-international-v-uruguay-decision/. Published July 8, 2016. Accessed March 20, 2019.
27
Garde A, Jefferey B, Rigby N. Implementing the WHO recommendations whilst avoiding real, perceived or potential conflicts of interest. Eur J Risk Regul. 2017;8(2):237-250.
28
World Health Organisation (WHO). Global strategy on diet, physical activity and health. Geneva: WHO; 2004.
29
World Health Organisation (WHO). Global strategy to reduce harmful use of alcohol. Geneva: WHO; 2011.
30
World Health Organisation (WHO). Framework of engagement with non-State actors. Geneva: WHO; 2016.
31
World Health Organisation (WHO). Global action plan for the prevention and control of noncommunicable diseases 2013-2020. Geneva: WHO; 2013.
32
Thow AM, Snowdon W, Labonte R, et al. Will the next generation of preferential trade and investment agreements undermine prevention of noncommunicable diseases? A prospective policy analysis of the Trans Pacific Partnership Agreement. Health Policy. 2015;119(1):88-96. doi:10.1016/j.healthpol.2014.08.002
33
Thow AM, McGrady B. Protecting policy space for public health nutrition in an era of international investment agreements. Bull World Health Organ. 2014;92(2):139-145. doi:10.2471/blt.13.120543
34
ORIGINAL_ARTICLE
It’s All About the IKT Approach: Three Perspectives on an Embedded Research Fellowship; Comment on “CIHR Health System Impact Fellows: Reflections on ‘Driving Change’ Within the Health System”
As a group of Health System Impact (HSI) postdoctoral fellows, Sim and colleagues offer their reflections on ‘driving change’ within the health system and present a framework for understanding the HSI fellow as an embedded researcher. Our commentary offers a different perspective of the fellow’s role by highlighting the integrated knowledge translation (IKT) approach we consider to be foundational to the fellowship experience. Further, we provide several recommendations to enhance Sim and colleagues’ framework to ensure we capture the full value of the fellowship program to the HSI fellow, health system organization, and academic institution.
https://www.ijhpm.com/article_3620_39a90c4ae47ff5401457fd9e7ab1a06e.pdf
2019-07-01
455
458
10.15171/ijhpm.2019.31
Integrated Knowledge Translation
Co-production
Embedded Researcher
Canada
Postdoctoral Training
Christine E.
Cassidy
christine.cassidy@iwk.nshealth.ca
1
IWK Health Centre, Halifax, NS, Canada
LEAD_AUTHOR
Stacy
Burgess
stacy.burgess@iwk.nshealth.ca
2
IWK Health Centre, Halifax, NS, Canada
AUTHOR
Ian D.
Graham
igraham@ohri.ca
3
School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada
AUTHOR
Canadian Institutes of Health Research. CIHR Health System Impact Fellowship. https://www.researchnet-recherchenet.ca. Published December 18, 2018. Accessed April 2, 2019.
1
Sim SM, Lai J, Aubrecht K, et al. CIHR health system impact fellows: reflections on “driving change” within the health system. Int J Health Policy Manag. 2019;8(6): 238-325. doi:10.15171/ijhpm.2018.124
2
Canadian Institutes of Health Research. Guide to Knowledge Translation Planning at CIHR: Integrated and End-of-Grant Approaches. http://www.cihr-irsc.gc.ca/e/45321.html#a3. Published 2012.
3
Kothari A, McCutcheon C, Graham ID. Defining integrated knowledge translation and moving forward: a response to recent commentaries. Int J Health Policy Manag. 2017;6(5):299-300. doi:10.15171/ijhpm.2017.15
4
Canadian Institutes of Health Research. CE Handbook - Chapter 6: Research Priority Setting and Integrated Knowledge Translation. http://www.cihr-irsc.gc.ca/e/42211.html. Published August 13, 2010. Accessed April 9, 2019.
5
Rycroft-Malone J, Burton CR, Bucknall T, Graham ID, Hutchinson AM, Stacey D. Collaboration and co-production of knowledge in healthcare: opportunities and challenges. Int J Health Policy Manag. 2016;5(4):221-223. doi:10.15171/ijhpm.2016.08
6
Bowen SJ, Graham ID. From knowledge translation to engaged scholarship: promoting research relevance and utilization. Arch Phys Med Rehabil. 2013;94(1 suppl):S3-8. doi:10.1016/j.apmr.2012.04.037
7
Gagliardi AR, Berta W, Kothari A, Boyko J, Urquhart R. Integrated knowledge translation (IKT) in health care: a scoping review. Implement Sci. 2016;11:38. doi:10.1186/s13012-016-0399-1
8
McIsaac J-LD, Penney TL, Storey KE, et al. Integrated knowledge translation in population health intervention research: a case study of implementation and outcomes from a school-based project. Health Res Policy Syst. 2018;16:72. doi:10.1186/s12961-018-0351-8
9
Bowen S, Botting I, Graham ID, Huebner L-A. Beyond “two cultures”: guidance for establishing effective researcher/health system partnerships. Int J Health Policy Manag. 2016;6(1):27-42. doi:10.15171/ijhpm.2016.71
10
ORIGINAL_ARTICLE
The Human Resources for Health Program in Rwanda: A Response to Recent Commentaries
https://www.ijhpm.com/article_3613_130f1644213fa80d9dfdd392d4fadb9f.pdf
2019-07-01
459
461
10.15171/ijhpm.2019.19
Human Resources for Health Program
Rwanda
Primary Care
Public Health
Corrado
Cancedda
corrado.cancedda@pennmedicine.upenn.edu
1
Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
LEAD_AUTHOR
Agnes
Binagwaho
vicechancellor@ughe.org
2
Office of the Vice-Chancellor, University of Global Health Equity, Kigali, Rwanda
AUTHOR
Delisle H. The Human Resources for Health Program in Rwanda – reflections on achievements and challenges; Comment on “Health professional training and capacity strengthening through international academic partnerships: the first five years of the Human Resources for Health Program in Rwanda.” Int J Health Policy Manag. 2019;8(2):128-131. doi:10.15171/ijhpm.2018.114
1
Dussault G. Reflections on health workforce development; Comment on “Health professional training and capacity strengthening through international academic partnerships: the first five years of the Human Resources for Health Program in Rwanda.” Int J Health Policy Manag. 2019;8(4):245-246. doi:10.15171/ijhpm.2018.129
2
Human resources for health strategic plan 2011-2016 - Ministry of Health. https://www.hrhresourcecenter.org/node/3738.html. Accessed March 31, 2019.
3
Binagwaho A, Farmer PE, Nsanzimana S, et al. Rwanda 20 years on: investing in life. Lancet. 2014;384(9940):371-375. doi:10.1016/s0140-6736(14)60574-2
4
D’Aquino L, Mahieu A. 2016 Rwanda: Comprehensive Evaluation of The Community Health Program in Rwanda. London, United Kingdom: London School of Tropical Medicine and Hygiene; 2016. https://www.unicef.org/evaldatabase/index_94535.html. Accessed March 26, 2019.
5
Farmer PE, Nutt CT, Wagner CM, et al. Reduced premature mortality in Rwanda: lessons from success. BMJ. 2013;346:f65. doi:10.1136/bmj.f65
6
Health. The World Bank website. https://data.worldbank.org/topic/health?display=&locations=RW. Accessed March 31, 2019
7
Rwanda: WHO and UNICEF estimates of immunization coverage: 2017 revision. WHO website. https://www.who.int/immunization/monitoring_surveillance/data/rwa.pdf. Accessed March 31, 2019.
8
7 Years Government Programme: National Strategy for Transformation (NST 1). Kigali, Rwanda: Ministry of Finance and Economic Planning; 2017. http://www.minecofin.gov.rw/fileadmin/user_upload/NST1_7YGP_Final.pdf. Accessed March 26, 2019.
9
Tackling Stunting: Rwanda’s Unfinished Business. The World Bank website https://www.worldbank.org/en/country/rwanda/publication/tackling-stunting-rwandas-unfinished-business. Accessed March 26, 2019. Published 2018.
10
Binagwaho A, Kyamanywa P, Farmer PE, et al. The human resources for health program in Rwanda--new partnership. N Engl J Med. 2013;369(21):2054-2059. doi:10.1056/NEJMsr1302176
11
Cancedda C, Cotton P, Shema J, et al. Health professional training and capacity strengthening through international academic partnerships: The first five years of the Human Resources for Health Program in Rwanda. Int J Health Policy Manag. 2018;7(11):1024-1039. doi:10.15171/ijhpm.2018.61
12
Price J, Binagwaho A. From medical rationing to rationalizing the use of human resources for AIDS care and treatment in Africa: a case for task shifting. Dev World Bioeth. 2010;10(2):99-103. doi:10.1111/j.1471-8847.2010.00281.x
13
Cancedda C, Farmer PE, Kerry V, et al. Maximizing the impact of training initiatives for health professionals in low-income countries: frameworks, challenges, and best practices. PLoS Med. 2015;12(6):e1001840. doi:10.1371/journal.pmed.1001840
14